{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vyvanse&page=2",
    "query": {
      "intervention": "Vyvanse",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vyvanse&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T05:47:15.431Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01760889",
      "title": "SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SPD489 low dose range (40mg, 80mg, and 100mg)",
          "type": "DRUG"
        },
        {
          "name": "SPD489 high dose range (120mg, 140mg and 160mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2013-02-01",
      "completion_date": "2013-04-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 4,
      "location_summary": "Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more",
      "locations": [
        {
          "city": "Miami Springs",
          "state": "Florida"
        },
        {
          "city": "O'Fallon",
          "state": "Missouri"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760889"
    },
    {
      "nct_id": "NCT01010750",
      "title": "Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Attention-Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine Dimesylate (LDX)",
          "type": "DRUG"
        },
        {
          "name": "Immediate Release Mixed Amphetamine Salts (MAS-IR)",
          "type": "DRUG"
        },
        {
          "name": "LDX Placebo + MAS-IR Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2010-01-05",
      "completion_date": "2010-03-28",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01010750"
    },
    {
      "nct_id": "NCT01435759",
      "title": "SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg",
          "type": "DRUG"
        },
        {
          "name": "Antidepressant + Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1197,
      "start_date": "2011-05-31",
      "completion_date": "2014-01-17",
      "has_results": true,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 60,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Chino, California + 54 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01435759"
    },
    {
      "nct_id": "NCT01760993",
      "title": "Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "SPD489",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2013-02-01",
      "completion_date": "2013-04-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 2,
      "location_summary": "Oklahoma City, Oklahoma • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760993"
    },
    {
      "nct_id": "NCT00500149",
      "title": "A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Vyvanse (lisdexamfetamine dimesylate)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 129,
      "start_date": "2007-06-13",
      "completion_date": "2007-12-05",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 9,
      "location_summary": "Little Rock, Arkansas • Irvine, California • Wildomar, California + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Wildomar",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00500149"
    },
    {
      "nct_id": "NCT01000064",
      "title": "Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Traumatic Brain Injury",
        "Attention Deficit Disorder"
      ],
      "interventions": [
        {
          "name": "Vyvanse",
          "type": "DRUG"
        },
        {
          "name": "fMRI",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "16 Years to 45 Years"
      },
      "enrollment_count": 22,
      "start_date": "2009-10",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2017-05-19",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01000064"
    },
    {
      "nct_id": "NCT01714310",
      "title": "Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Mood Dysregulation"
      ],
      "interventions": [
        {
          "name": "lisdexamfetamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "fluoxetine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 34,
      "start_date": "2013-01",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-02-26",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01714310"
    },
    {
      "nct_id": "NCT00807222",
      "title": "Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder",
        "Sleep"
      ],
      "interventions": [
        {
          "name": "lisdexamfetamine dimesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clinical Study Centers, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-04",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2008-12-11",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807222"
    },
    {
      "nct_id": "NCT00248092",
      "title": "Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity",
        "Amphetamine-Related Disorders",
        "Substance-Related Disorders"
      ],
      "interventions": [
        {
          "name": "NRP104",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New River Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2006-01",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2007-11-05",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248092"
    },
    {
      "nct_id": "NCT01986764",
      "title": "E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Planned RRSO"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine",
          "type": "DRUG"
        },
        {
          "name": "Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "48 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 48 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2013-07-01",
      "completion_date": "2013-07-01",
      "has_results": false,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-09-16T05:47:15.431Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01986764"
    }
  ]
}